Master Rollover Protocol for Continued Safety Assessment of Study Drug
NCT02632994 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-09-29
Summary
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
Conditions
Interventions
- DRUG
-
LY2503029
Administered orally.
- DRUG
-
LY3023414
Administered orally.
- DRUG
-
LY3838915
Administered orally.
- DRUG
-
LY3847429
Administered orally.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Study of LY2624587 in Patients With Advanced Cancer
NCT01139788 ·Status: COMPLETED ·Phase: PHASE1
-
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
NCT02561455 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
NCT02597036 ·Status: TERMINATED ·Phase: PHASE1
-
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
NCT05201066 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
NCT01520220 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
NCT07258836 ·Status: RECRUITING ·Phase: PHASE1
-
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
NCT02599649 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
NCT06205290 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
NCT05829226 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase 1 Study of LY2787106 in Cancer and Anemia
NCT01340976 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Myeloproliferative Disorders
NCT01134120 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator
NCT01802879 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
NCT07008118 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of LY3410738 in Healthy Adult Participants
NCT06181045 ·Status: COMPLETED ·Phase: PHASE1
-
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
NCT02948283 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
NCT03793140 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
NCT00621244 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
NCT05519579 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
NCT02494258 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
NCT02281084 ·Status: COMPLETED ·Phase: PHASE2
-
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
NCT00004258 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00602836 ·Status: COMPLETED ·Phase: PHASE2
-
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3